A scientific morning session on the novel and superior treatment for Respiratory Distress Syndrome (RDS), introducing the molecule Calfactant under the American brand Infasurf, was held on Sunday, August 11, 2024, at Akbarabadi Hospital in Tehran by Kimia Ara company.
In this session, Dr. Rahimi, the medical advisor of the company, discussed the structure of natural surfactant and compared it with the components of Calfactant in terms of structural and functional similarities. A comparison was also presented, highlighting the superiority of Calfactant based on its composition and performance over other surfactant brands. It was revealed that compared to other brands available in the Iranian market, Calfactant has lower surface and dynamic viscosity, which significantly aids in its better absorption, quicker, and easier spread in the alveolar sacs of the lungs.
Additionally, Calfactant reduces surface tension to zero, which improves the lung’s respiratory capacity and prevents the collapse of alveolar sacs during exhalation. The session emphasized that the single-dose effectiveness of Calfactant compared to other brands enhances respiratory indices, reduces the need for oxygen therapy, and shortens the hospitalization period. From the Professors’ viewpoint, the success of Calfactant in requiring fewer repeated doses and not needing mixing or warming during preparation for injection has made it cost-effective and endorsed by physicians for use in clinical settings.
Currently, the only Calfactant brand available in Iran market is Infasurf, which is imported as a finished product from ONY Biotech America in 3 and 6-milliliter volumes by Kimia Ara company.
This scientific morning session was held with the presence of esteemed neonatology specialists:
- Dr. Arash Bordbar (Head of Akbarabadi Hospital)
- Dr. Majid Kalani (Head of the NICU at Akbarabadi Hospital)
- Dr. Mandana Keshaki
- Dr. Ali Mazoori
- Dr. Maryam Sabouteh
As well as pediatric residents, interns, and head nurses and nurses of the NICU on Sunday, August 11, 2024.
